Biodexa Pharmaceuticals (BDRX) Revenue (2015 - 2021)

Biodexa Pharmaceuticals (BDRX) has 5 years of Revenue data on file, last reported at $540552.3 in Q4 2021.

• For the quarter ending Q4 2021, Revenue rose 5017.12% year-over-year to $540552.3; the trailing twelve-month figure through Dec 2021 stood at $856906.8 (down 33.05% YoY), and the FY2023 full-year result was $473896.6, down 45.22% from the prior year.
• Revenue advanced to $540552.3 in Q4 2021, from $10563.6 in the prior quarter.
• In the past five years, Revenue ranged from a high of $540552.3 in Q4 2021 to a low of $10074.2 in Q3 2020.
• A 3-year average of $214226.7 and a median of $153140.2 in 2020 frame the typical range for Revenue.
• Across the five-year window, Revenue sank 96.43% in 2020 and jumped 5017.12% in 2021, its largest moves.
• Tracing BDRX's Revenue over 3 years: stood at $295716.7 in 2019, then slumped by 96.43% to $10563.6 in 2020, then surged by 5017.12% to $540552.3 in 2021.
• Business Quant data shows BDRX's Revenue at $540552.3 in Q4 2021, $10563.6 in Q4 2020, and $10074.2 in Q3 2020.